A Break from Chemo: PARP Inhibitor Shrinks Tumors in Pancreatic Cancer Patients with Mutations

Published by W Butcher on

More than two-thirds of pancreatic cancer patients harboring genetic mutations saw their tumor stop growing or shrink substantially after being switched from intensive chemotherapy to the PARP inhibitor rucaparib as a maintenance therapy, researchers from the Abramson Cancer Center at the University of Pennsylvania reported online today in the Journal of Clinical Oncology. The results from the phase II trial at the ACC support the use rucaparib for pancreatic cancer patients with BRCA1BRCA2, and PALB2 variantsto help control tumor growth without the aggressive side effects of chemotherapy.

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.